Posted by: bitty Date: Thursday, January 21, 2010 8:41:25 AM
In reply to: None Post # of 5577
This is Brian Culley's Response - so tomorrow's article should be very good for ANX!
I am doing my own article, but it won't be out until Monday. Here is the exact email from Brian Culley responding to Monday's Adam F.'s blog:
"Hi Traci,
Thanks for the link and for your interest in ADVENTRX. Interestingly, the highly-bearish A.F. valued us at our current market price with zero value ascribed to ANX-514 (or our cash)...effectively calling us a buy, but I do not expect it will be seen that way by his readers. I deeply respect A.F.'s right to hold and publish his opinions, and I welcome the scrutiny of informed analysts, but his two reports are filled with comments which reflect not only a different set of assumptions (e.g. he pulls a 2X premium for ANX-530 out of thin air), but moreover, a juvenile understanding of the basic workings of functional areas such as regulatory or commercialization. For example, he states that additional clinical data will be required in Europe. Unless he paid $60,000 to hold a scientific advice meeting with EMEA and discussed our data package with them, that's a wild-ass assumption which lies outside of our product profile (and one he makes despite my telling him about the EMEA hybrid application process). Or another example, he called our market research data "biased". The fact is, we commisioned a highly-respected, independent third-party to conduct an anonymous and robust conjoint analysis of 70 oncologists. We can't "unbias" it any more that that without avoiding the study altogether. And the market research firm's impeccable reputation is based on accuracy, not on feeding us big numbers (I don't want to hear big numbers if they are BS, I need the best estimate available to build a sustainable business). And although we think our strongest market penetration will be with community docs, we had both community and hospital docs polled - so we went out of our way to avoid a potential bias. Frankly, I could go on and on in painful detail on each and every point, but it's an inapropriate distraction for me to engage in a detailed dialog with every blogger. I do hope his readership (and our stockholders) will follow the company closely, educate themselves about the pharmaceutical industry, and come to independent decisions about their investments rather than follow the fleeting barks of outsiders. In the meantime, we will continue, as we have for years, and as virtually every other company does, to use conference presentations as a way to communicate and update our story to a wide audience, and if we become aware of certain issues arise that merit clarity, we incorporate those facts into our ever-evolving presentation. Stay in touch and thanks again for the link.
Best,
Brian"
This is Traci Hogg and I will be doing a follow up article. I personally believe that Adam F. has an agenda and that was to buy ANX much lower (after his articles did some damage.) This stock is a SCREAMING STRONG BUY! |
Thread abonnieren
